The Effect of Smoking and Opioid Consumption on the Severity of the Disease and Duration of Hospitalization in COVID-19 Patients
DOI:
https://doi.org/10.2478/AMB-2023-0005Keywords:
COVID-19, SARS-CoV-2, opioid abuse, smoking, opioidAbstract
Objective
In the Coronavirus 2019 (COVID-19) global pandemic, various studies on the target communities of this virus were widely started and rapidly progressed. Smokers and opioid consumers are one of the virus targets since they have a vulnerable respiratory system. Due to the contradictory results in previous studies and the lack of similar investigations in this area, we aimed to perform this study to investigate the effect of smoking and opioid consumption on the consequences of the COVID-19 disease.
Materials and Methods
In this retrospective study, the required information was collected and analyzed from the archives of Razi Hospital, Rasht, Iran. Study variables included age, sex, the need for intubation, hospital length of stay, history of current smoking or opioid consumption, and intensive care unit (ICU) admission, ICU length of stay, admission oxygen saturation, disease severity, and the outcome of death or recovery. Data were collected and divided into the case (including current cigarette smokers, opioid consumers, and cigarette-opioid consumers) and control (non-smokers and non-opioid-consumers) groups. Out of 986 patients, 489 patients met the criteria for inclusion and subsequent analysis. The average age was 69.79 ± 16.06, and 294 (60.1%) patients were male. The median age of the case group (65.15 ± 42.41) was older than the control group (57.45 ± 15.71, P = 0.001). The case group consisted of more male patients than the control group (P = 0.001).
Results
The adjusted regression models demonstrated that current cigarette smoking, opioid, and cigarette-opioid consumption did not significantly predict hospital and ICU length of stay, ICU admission, disease severity, and mortality outcomes (P > 0.05). Current cigarette smoking and opioid consumption could not be an independent predictor for the consequences of ICU admission, hospital and ICU length of stay, the need for intubation, disease severity, and mortality in COVID-19 patients.
References
Halaji M, Heiat M, Faraji N, Ranjbar R. Epidemiology of COVID-19: An updated review. J Res Med Sci [Internet]. 30 September 2021;26:82. Available at: https://pubmed.ncbi.nlm.nih.gov/34759999
Hardenbrook NJ, Zhang P. A structural view of the SARS-CoV-2 virus and its assembly. Curr Opin Virol. 2022;52:123–34.
Samavati L, Uhal BD. ACE2, Much More Than Just a Receptor for SARS-COV-2. Vol 10, Frontiers in Cellular and Infection Microbiology. 2020.
Zeinali T, Faraji N, Joukar F et al. Gut bacteria, bacteriophages, and probiotics: Tripartite mutualism to quench the SARS-CoV2 storm. Microb Pathog [Internet]. 2022;105704. Available at: https://www.sciencedirect.com/science/article/pii/S0882401022003175
Anastassopoulou C, Gkizarioti Z, Patrinos GP, Tsakris A. Human genetic factors associated with susceptibility to SARS-CoV-2 infection and COVID-19 disease severity. Hum Genomics [Internet]. 2020;14(1):40. Available at: https://doi.org/10.1186/s40246-020-00290-4
Yaghubi T, Shakoori V, Nasiri S et al. Clinical characteristics and outcomes of COVID-19 patients with a history of cardiovascular disease. J Curr Biomed Reports. 2022.
Reddy RK, Charles WN, Sklavounos A et al. The effect of smoking on COVID-19 severity: A systematic review and meta-analysis. J Med Virol. Februarie 2021;93(2):1045-56.
Eastin C, Eastin T. Clinical Characteristics of Coronavirus Disease 2019 in China: Guan W, Ni Z, Hu Y, et al. N Engl J Med. 2020 Feb 28 [Online ahead of print] DOI: 10.1056/NEJMoa2002032. J Emerg Med [Internet]. 2020/06/03. April 2020;58(4):711-2. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7266766/
Rossato M, Russo L, Mazzocut S et al. Current smoking is not associated with COVID-19. The European respiratory journal. 2020, 55.
Hopkinson NS, Rossi N, El-Sayed Moustafa J et al. Current smoking and COVID-19 risk: results from a population symptom app in over 2.4 million people. Thorax. Julie 2021;76(7):714-22.
Yu X, Sun X, Cui P et al. Epidemiological and clinical characteristics of 333 confirmed cases with coronavirus disease 2019 in Shanghai, China. Transbound Emerg Dis. Julie 2020;67(4):1697–707.
Gülsen A, Yigitbas BA, Uslu B et al. The Effect of Smoking on COVID-19 Symptom Severity: Systematic Review and Meta-Analysis. Pulm Med [Internet]. 08 September 2020;2020:7590207. Available at: https://pubmed.ncbi.nlm.nih.gov/32963831
Lippi G, Henry BM. Active smoking is not associated with severity of coronavirus disease 2019 (COVID-19). Eur J Intern Med. 2020;75:107–8.
West R. Tobacco smoking: Health impact, prevalence, correlates and interventions. Psychol Health. 2017/05/28. Augustus 2017;32(8):1018–36.
Strzelak A, Ratajczak A, Adamiec A, Feleszko W. Tobacco Smoke Induces and Alters Immune Responses in the Lung Triggering Inflammation, Allergy, Asthma and Other Lung Diseases: A Mechanistic Review. Int J Environ Res Public Health. Mei 2018;15(5).
Liu W, Tao Z-W, Wang L et al. Analysis of factors associated with disease outcomes in hospitalized patients with 2019 novel coronavirus disease. Chin Med J (Engl). Mei 2020;133(9):1032-8.
Alqahtani JS, Aldhahir AM, Oyelade T et al. Smoking cessation during COVID-19: the top to-do list. NPJ Prim care Respir Med. Mei 2021;31(1):22.
Ho KS, Narasimhan B, Sheehan J et al. Controversy over smoking in COVID-19-A real world experience in New York city. J Med Virol. Julie 2021;93(7):4537–43.
Simons D, Shahab L, Brown J, Perski O. The association of smoking status with SARS-CoV-2 infection, hospitalization and mortality from COVID-19: a living rapid evidence review with Bayesian meta-analyses (version 7). Addiction. Junie 2021;116(6):1319–68.
Usman MS, Siddiqi TJ, Khan MS et al. Is there a smoker’s paradox in COVID-19? BMJ evidence-based Med. Desember 2021;26(6):279–84.
Khalili P, Ayoobi F, Mohamadi M et al. Effect of opium consumption on cardiovascular diseases – a cross-sectional study based on data of Rafsanjan cohort study. BMC Cardiovasc Disord [Internet]. 2021;21(1):2. Available at: https://doi. org/10.1186/s12872-020-01788-4
Mehrabi S, Delavari A, Moradi G et al. Smoking among 15- to 64-Year-Old Iranian People in 2005. irje [Internet]. 01 September 2007;3(1):1–9. Available at: http://irje.tums.ac.ir/article-1-165-en.html
Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet [Internet]. 15 Februarie 2020;395(10223):497–506. Available at: https://doi.org/10.1016/S0140-6736(20)30183-5
Chen Q, Zheng Z, Zhang C et al. Clinical characteristics of 145 patients with corona virus disease 2019 (COVID-19) in Taizhou, Zhejiang, China. Infection [Internet]. 2020/04/28. Augustus 2020;48(4):543–51. Available at: https://pubmed.ncbi. nlm.nih.gov/32342479
Zhou F, Yu T, Du R et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet (London, England). Maart 2020;395(10229):1054–62.
Alqahtani JS, Oyelade T, Aldhahir AM et al. Prevalence, Severity and Mortality associated with COPD and Smoking in patients with COVID-19: A Rapid Systematic Review and Meta-Analysis. PLoS One. 2020;15(5):e0233147.
Samet JM. Tobacco Products and the Risks of SARS-CoV-2 Infection and COVID-19. Nicotine Tob Res [Internet]. 01 Desember 2020;22(Supplement_1):S93–5. Available at: https://doi.org/10.1093/ntr/ntaa187
Farsalinos K, Barbouni A, Niaura R. Systematic review of the prevalence of current smoking among hospitalized COVID-19 patients in China: could nicotine be a therapeutic option? Intern Emerg Med. Augustus 2020;15(5):845–52.
Zureik M, Baricault B, Vabre C et al. Nicotine-replacement therapy, as a surrogate of smoking, and the risk of hospitalization with Covid-19 and all-cause mortality: a nationwide, observational cohort study in France. medRxiv [Internet]. 01 Januarie 2020;2020.07.28.20160630. Available at: http://medrxiv.org/content/early/2020/07/30/2020.07.28.20160630.abstract
Farsalinos K, Niaura R, Le Houezec J et al. Editorial: Nicotine and SARS-CoV-2: COVID-19 may be a disease of the nicotinic cholinergic system. Toxicology reports. 2020,7,658-63.
Oakes JM, Fuchs RM, Gardner JD et al. Nicotine and the renin-angiotensin system. Am J Physiol Regul Integr Comp Physiol. November 2018;315(5):R895-906.
Yue X, Basting TM, Flanagan TW et al. Nicotine Downregulates the Compensatory Angiotensin-Converting Enzyme 2/Angiotensin Type 2 Receptor of the Renin–Angiotensin System. Annal Am Thorac Soc, 2018;15, bl S126-7.
Qeadan F, Mensah NA, Tingey B et al. The association between opioids, environmental, demographic, and socioeconomic indicators and COVID-19 mortality rates in the United States: an ecological study at the county level. Arch Public Heal [Internet]. 2021;79(1):101. Available at: https://doi. org/10.1186/s13690-021-00626-z
Riahi T, Sadeghzadeh-Bazargan A, Shokri S et al. The effect of opium on severity of COVID-19 infection:An original study from Iran. Med J Islam Repub Iran. 2021;35:115.
Chadzinska M, Kolaczkowska E, Seljelid R, Plytycz B. Morphine modulation of peritoneal inflammation in Atlantic salmon and CB6 mice. J Leukoc Biol [Internet]. 01 Mei 1999;65(5):590-6. Available at: https://doi.org/10.1002/jlb.65.5.590
Roy S, Loh HH. Effects of opioids on the immune system. Neurochem Res. November 1996;21(11):1375-86.
Dolati-Somarin A, Abd-Nikfarjam B. The Reasons for Higher Mortality Rate in Opium Addicted Patients with COVID-19: A Narrative Review. Iran J Public Health. Maart 2021;50(3):470-9.
McBride PE. The health consequences of smoking. Cardiovascular diseases. Med Clin North Am. Maart 1992;76(2):333–53.
Fang X, Li S, Yu H et al. Epidemiological, comorbidity factors with severity and prognosis of COVID-19: a systematic review and meta-analysis. Aging (Albany NY) [Internet]. 2020/07/13. 13 Julie 2020;12(13):12493–503. Available at: https://pubmed.ncbi.nlm.nih.gov/32658868
Downloads
Published
Issue
Section
License
Copyright (c) 2023 Acta Medica Bulgarica
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
You are free to share, copy and redistribute the material in any medium or format under these terms.
Journal Acta Medica Bulgarica 
